2024-10-17 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops and manufactures innovative medicines for patients with serious illnesses.

**1. Performance Comparison with S&P 500 (VOO):**

* **Cumulative Return (AMGN):** 81.8%
* **Cumulative Return (VOO):** 135.94%
* **Performance Gap:** -54.14%
* **Relative Performance:** 31.89% (This means AMGN's performance has been lower than VOO's over the observed period, but it is located at the 31.89th percentile of the performance range).

**2. Recent Price Movements:**

* **Closing Price:** $325.09
* **5-Day Moving Average:** $324.3
* **20-Day Moving Average:** $324.54
* **60-Day Moving Average:** $327.19

**3. Technical Indicators:**

* **RSI:** 62.91 (Indicates a neutral to slightly overbought condition)
* **PPO:** 0.16 (Positive, suggesting a potential buy signal)
* **Delta_Previous_Relative_Divergence:** -10.87 (Negative, suggesting a potential short-term downward trend)
* **Expected_Return:** 0.0% (This suggests a 5-year expected return of 0% compared to the S&P 500, reflecting the current market conditions and investor sentiment)

**4. Recent Earnings and Forecasts:**

| Date       | EPS    | Revenue   |
|------------|--------|-----------|
| 2024-08-07 | 1.39   | 8.39 B$   |
| 2024-05-03 | -0.21  | 7.45 B$   |
| 2023-10-31 | 3.23   | 6.90 B$   |
| 2023-08-04 | 2.58   | 6.99 B$   |
| 2024-08-07 | 2.58   | 6.99 B$   |

The most recent earnings report for Q2 2024 (released on August 7th, 2024) showed an EPS of $1.39, beating analysts' expectations of $1.15. Revenue also exceeded expectations, coming in at $8.39 billion compared to the projected $8.24 billion. 

**5. News and Recent Developments:**

* **Recent Market Outlook:** Amgen's stock has been experiencing some volatility in recent months, mirroring broader market trends. However, analysts remain optimistic about the company's long-term growth prospects, driven by its strong pipeline of new drugs and its established presence in the biopharmaceutical market.
* **Analyst Opinions:** Most analysts have a “Buy” or “Strong Buy” rating on AMGN, with a consensus price target of around $350.
* **Performance Highlights:**  Amgen continues to invest heavily in research and development, with several promising new therapies in late-stage clinical trials. 
* **News and Issues:**  Follow FINBOLD, Yahoo Finance, and other financial news sources to stay updated on Amgen's latest news and events, including any regulatory updates, new product launches, and analyst ratings. 

**6.  Comprehensive Analysis:**

AMGN is a leading player in the biotechnology industry, boasting a strong portfolio of existing products and a promising pipeline of new therapies. While recent performance has been somewhat muted compared to the S&P 500, the company's solid fundamentals and strong earnings performance suggest potential for future growth. However, investors should be aware of the current market volatility and consider the risks associated with the biotechnology sector.  

**7.  Key Takeaways for Investors:**

* **Long-term growth potential:** Amgen's strong R&D pipeline and existing product portfolio suggest potential for long-term growth.
* **Current market volatility:** The stock is currently experiencing some volatility, which reflects broader market trends. 
* **Analyst optimism:** Many analysts remain optimistic about AMGN's prospects and believe the stock is undervalued.
* **Risk assessment:**  As with any biotechnology stock, there is a risk associated with the development and approval of new therapies.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Always consult with a qualified financial professional before making any investment decisions. 
